Axsome Therapeutics Stock: 12 Straight Red Days, Down 15%
Shares of Axsome Therapeutics (AXSM) have closed lower in each of the last 12 sessions, a cumulative decline of 15.3%. That erased about $1.6 billion from the company’s market value, which now stands at about $8.6 billion. The stock closed at $166.00 on Monday, October 12, 34.9% below its 52-week high of $255.17 and 37.0% above its low of $121.15.
How The Streak Stacks Up Against The S&P 500
Returns for AXSM and the S&P 500 over the streak and the periods around it, all ending Monday, October 12 and including dividends:
| Return Period | AXSM | S&P 500 |
|---|---|---|
| 1 Day | -1.4% | -0.1% |
| 12 Days (Current Streak) | -15.3% | 1.4% |
| 1 Month (21 Trading Days) | -24.8% | 2.0% |
| 3 Months (63 Trading Days) | -29.4% | 3.8% |
| Year To Date | -9.1% | 15.1% |
| 1 Year (252 Trading Days) | 35.5% | 17.3% |
A Stock-Specific Slide, Or A Market Move?
The market explains little of this: the S&P 500 gained 1.4% over the same 12 sessions, including dividends, against Axsome Therapeutics’ -15.3%. Over the past three months the stock is down 29.4%, a window that includes the streak; over the other 51 sessions of that window it was down 16.7%.
What The Numbers Say About The Slide
On the fundamentals, revenue grew 56.9% over the last twelve months, against a median of 8.1% for S&P 500 Health Care stocks; and its operating margin is -23.5%, versus a median of 17.6%. Axsome Therapeutics does not have positive trailing earnings, so there is no meaningful price-to-earnings multiple to compare. The fundamentals give the sellers some support: an operating loss.
A slide like this raises an obvious follow-up: which marked-down stocks are actually worth buying? Our Buy the Dip screen runs that test every day, flagging beaten-down names whose fundamentals still hold up.
A Slide Like This Is Why Diversification Exists
Watching one stock fall day after day is the clearest lesson the market teaches about single-name risk. Whether this particular decline is an opportunity or a warning, the deeper point is the same: no one name should be able to do this to your portfolio.
The Trefis High Quality (HQ) Portfolio is built on that principle: roughly 30 businesses selected for consistent cash generation, strong margins, and resilient balance sheets, sized and rebalanced with rules. It has a track record of outpacing a benchmark that combines the S&P 500, the S&P MidCap 400, and the Russell 2000. Study the slide; spread the risk.